p53 Function in Tumor-Associated Stromal Cells
Author Information
Author(s): Dudley A C, Shih S-C, Cliffe A R, Hida K, Klagsbrun M
Primary Institution: Children's Hospital and Harvard Medical School
Hypothesis
Alterations in p53 function in tumor-associated stromal cells may affect their sensitivity to p53-activating drugs.
Conclusion
Tumor-associated stromal cells exhibit impaired p53 function, leading to decreased sensitivity to chemotherapeutic drugs and genomic instability.
Supporting Evidence
- Stromal cells from tumors showed diminished p53 expression after treatment with p53-activating drugs.
- These cells failed to undergo apoptosis and cell cycle arrest in response to chemotherapy.
- Alterations in p53 function were associated with genomic instability in tumor-associated stromal cells.
Takeaway
The study found that the cells around tumors don't respond well to cancer drugs because they have problems with a protein called p53, which usually helps control cell growth.
Methodology
The study used tumor-associated stromal cells from melanoma and prostate carcinoma models to assess p53 activation and drug sensitivity.
Limitations
The study does not address the specific mechanisms behind the impaired p53 function in tumor-associated stromal cells.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website